Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives $23.57 Average PT from Analysts

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) have earned an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $23.57.

A number of equities research analysts recently weighed in on TEVA shares. UBS Group dropped their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. StockNews.com cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. Barclays decreased their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st.

Insider Transactions at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the transaction, the director now directly owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. This represents a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the sale, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at $744,034.48. This trade represents a 30.54 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.55% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Oarsman Capital Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $29,000. UMB Bank n.a. boosted its holdings in Teva Pharmaceutical Industries by 555.6% during the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after buying an additional 2,067 shares in the last quarter. Smithfield Trust Co grew its position in Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after buying an additional 980 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in Teva Pharmaceutical Industries in the third quarter valued at $50,000. Finally, Claro Advisors LLC acquired a new position in shares of Teva Pharmaceutical Industries in the third quarter worth about $52,000. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Trading Up 1.5 %

NYSE TEVA opened at $16.59 on Friday. The company’s 50-day simple moving average is $20.01 and its two-hundred day simple moving average is $18.50. Teva Pharmaceutical Industries has a one year low of $12.51 and a one year high of $22.80. The company has a market capitalization of $18.79 billion, a price-to-earnings ratio of -11.44, a price-to-earnings-growth ratio of 1.39 and a beta of 0.71. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.61 and a current ratio of 0.98.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Equities analysts forecast that Teva Pharmaceutical Industries will post 2.62 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.